PHATHOM PHARMACEUTICALS, INC. Payments for Restructuring
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Payments for Restructuring of $405.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2026-06-30 was $97.00K.
- PHATHOM PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2026-03-31 was $308.00K.
- PHATHOM PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2025-12-31 was $883.00K.
- PHATHOM PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2025-09-30 was $1.14M.
- PHATHOM PHARMACEUTICALS, INC. payments for restructuring for fiscal 2025 was $4.13M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $405.00K 10-Q · filed 2026-07-30 | $1.29M derived: sum of 3 quarters · filed 2026-07-30 | $2.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $308.00K 10-Q · filed 2026-04-30 | $1.19M derived: sum of 2 quarters · filed 2026-04-30 | $2.33M derived: sum of 3 quarters · filed 2026-04-30 | |
| 2025-12-31 | $883.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.02M derived: sum of 2 quarters · filed 2026-02-26 | $4.13M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.24M 10-Q · filed 2025-10-30 | ||
| 2025-06-30 | $2.10M 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |